Hetero Drugs
Hetero Drugs Limited, commonly referred to as Hetero, is a prominent player in the global pharmaceutical industry, headquartered in Hyderabad, India. Established in 1993, the company has made significant strides in the development and manufacturing of a diverse range of generic and branded medications, particularly in the areas of anti-retrovirals, oncology, and cardiovascular treatments. With a strong presence in over 120 countries, Hetero is recognised for its commitment to quality and affordability, making essential medicines accessible to patients worldwide. The company’s extensive portfolio includes over 200 products, distinguished by their rigorous quality standards and innovative formulations. Hetero's dedication to research and development has positioned it as a leader in the pharmaceutical sector, contributing to its reputation for excellence and reliability in healthcare solutions.
DitchCarbon Score
How does Hetero Drugs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hetero Drugs's score of 24 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hetero Drugs's reported carbon emissions
In 2024, Hetero Drugs reported total greenhouse gas emissions of approximately 405,663,000 kg CO2e, which includes 196,106,000 kg CO2e from Scope 1 and 209,557,000 kg CO2e from Scope 2 emissions. This represents a slight decrease from 2023, where total emissions were about 412,461,000 kg CO2e, with Scope 1 emissions at 213,330,000 kg CO2e and Scope 2 emissions at 199,131,000 kg CO2e. Over the past few years, Hetero Drugs has shown a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. The company has not reported any Scope 3 emissions, indicating a focus on direct and indirect emissions from its operations and energy use. Hetero Drugs operates with a GHG intensity of approximately 2.64e-06 kg CO2e per unit of revenue, reflecting its operational efficiency in relation to emissions. The company has not cascaded any emissions data from a parent or related organization, indicating that its reported figures are independently sourced. Overall, while Hetero Drugs has made strides in managing its emissions, further transparency regarding specific reduction commitments and initiatives would enhance its climate accountability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 222,286,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 117,362,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hetero Drugs is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
